Caspofungin in Combination with Itraconazole for the Treatment of Invasive Aspergillosis in Humans
The DOI matches its Crossref record.
Abstract
SIR—Caspofungin (Cancidas; Merck) belongs to a new class of antifungal agents, the echinocandins. It has in vitro fungicidal activity against numerous fungal pathogens, including Aspergillus species. Although no published studies have evaluated the use of caspofungin for treatment of invasive aspergillosis (IA) in humans, limited data have been reported that clinical improvement or complete response occurred in 41% of caspofungin-treated patients with IA who were intolerant of or had infections refractory to standard antifungal therapies [1]. No clinical data exist on the use of caspofungin in combination with other antifungal agents, which is an intriguing possibility, given caspofungin's unique mechanism of action. We report our experience with the use of caspofungin in combination with itraconazole in 2 immunocompromised patients with IA. The first patient was a 50-year-old woman with acute lymphoblastic leukemia who underwent induction chemotherapy. By day 28 of chemotherapy, she was not in remission, so she underwent reinduction and soon developed neutropenic fever and a dry cough. Administration of broad-spectrum antibiotics was started, and a chest radiograph revealed right upper and right lower lobe opacities. A thoracic CT scan revealed a cavitary lesion in the right lower lobe. Shortly thereafter, the patient complained of pain and rapidly progressive vision loss in her right eye. Bronchoscopic evaluation with lavage and vitrectomy were performed. Cultures of samples obtained from both procedures grew Aspergillus terreus, an amphotericin B–resistant organism. The patient received caspofungin (50 mg/day given iv) and itraconazole (200 mg t.i.d. given by mouth [po]), which she tolerated well. She stabilized clinically and underwent right lower lobectomy 4 weeks later. She received a total of 8 weeks of combination antifungal therapy. Five weeks after completing therapy, she underwent bone marrow transplantation; although the transplantation was not successful, she remained free of Aspergillus infection for >7 months before dying of leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 658
Combination Antifungal Therapy for Invasive Aspergillosis
Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L. (2004) · Clinical Infectious Diseases · doi:10.1086/423380 · Cited by 596
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
“416, 2002), itraconazole (170), or voriconazole (Gentina et al.”
Background
Metadata
- Authors
- Rubin, M. A., Carroll, K. C., & Cahill, B. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-04-15
- Volume
- 34
- Issue
- 8
- Pages
- 1160-1161
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2035534929
- Cited by
- 76
- References
- 0
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caspofungin in Combination with Itraconazole for the Treatment of Invasive Aspergillosis in Humans. https://app.cochat.ai/papers/10.1086/339755
- The paper
- Rubin, M. A., Carroll, K. C., & Cahill, B. C. (2002). Caspofungin in Combination with Itraconazole for the Treatment of Invasive Aspergillosis in Humans. Clinical Infectious Diseases. https://doi.org/10.1086/339755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.